Clinical Trials Browser

Recruiting × Lymphoma, T-Cell × Cyclophosphamide × Clear all

Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03017820 2026-04-13

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

Immunoblastic Lymphadenopathy, Multiple Myeloma, Mycosis Fungoides, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

NCT06390319 2026-02-27

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

Phase 2 Recruiting

100 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Biphenotypic, Acute, Lymphoma, T-Cell, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03125642 2025-11-04

Auto Stem Cell Transplant for Lymphoma Patients

Phase 2 Recruiting

150 enrolled

LymphoidOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05805605 2025-07-01

Allo HSCT Using RIC and PTCy for Hematological Diseases

Phase 2 Recruiting

56 enrolled

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Burkitt Lymphoma, Leukemia, Myeloid, Leukemia, Plasma Cell, Lymphoma, Follicular, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, Prolymphocytic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Lymphoma, B-Cell, Marginal Zone, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

NCT06699771 2025-04-30

Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies

Phase 1 Recruiting

48 enrolled

Lymphoid

Lymphoma, T-Cell

NCT06224049 2024-03-12

GI-hNeoT-01

Phase EARLY_PHASE1 Recruiting

6 enrolled

Lymphoid

Lymphoma, T-Cell, Epstein-Barr Virus Infections

Clinical Trials

Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

Auto Stem Cell Transplant for Lymphoma Patients

Allo HSCT Using RIC and PTCy for Hematological Diseases

Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies

GI-hNeoT-01